This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OXiGENE Reports Second Quarter 2012 Financial Results

Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

OXiGENE, Inc.    
Balance Sheet Data    
(Unaudited)    
  June 30, 2012 December 31, 2011
   (All amounts in 000's) 
Assets     
     
Cash and restricted cash  $ 6,922  $ 9,992
Prepaid expenses  460  582
License agreement  240  289
Other assets  114  193
     
Total assets  $ 7,736  $ 11,056
     
     
Liabilities and stockholders' equity    
     
Accounts payable and accrued liabilities  $ 1,617  $ 2,253
Derivative liabilities  1  6
Total stockholders' equity   6,118  8,797
     
Total liabilities and stockholders' equity   $ 7,736  $ 11,056
         
         
OXiGENE, Inc.         
Statement of Operations Data         
(Unaudited)  Three months ended June 30,   Six months ended June 30, 
  2012 2011 2012 2011
   (All amounts in 000's except per share amounts) 
Product revenue  $ -  $ -  $ 114  $ -
         
Operating Expenses:        
         
Research and development 1,080 1,499 1,734 3,182
General and administrative  1,199  1,401  2,531  2,786
Restructuring  (2)  -  11  -
         
Total operating expenses  2,277  2,900  4,276  5,968
         
Loss from Operations  (2,277)  (2,900)  (4,162)  (5,968)
         
Change in fair value of warrants  4  (31)  5  2,179
Investment income  3  1  8  2
Other (expense) income, net  4  (2)  (8)  (8)
         
Net loss  $ (2,266)  $ (2,932)  $ (4,157)  $ (3,795)
         
Basic and diluted net loss per common share  $ (0.14)  $ (0.32)  $ (0.26)  $ (0.49)
Weighted average number of common shares outstanding   16,484  9,110  16,104  7,820
CONTACT: Investor and Media Contact:
         ir@oxigene.com
         650-635-7000

company logo

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs